Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup
| Autor: | Rita Nemr, Roland Moufarrege, Emile Andari, Akram Echtay, Paola Atallah |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Epidemiology Original Report: Diabetes Administration Oral 030209 endocrinology & metabolism Type 2 diabetes 030204 cardiovascular system & hematology Hypoglycemia 03 medical and health sciences Young Adult 0302 clinical medicine Insulin Detemir Internal medicine medicine Humans Hypoglycemic Agents Prospective Studies Adverse effect Prospective cohort study Developing Countries Insulin detemir Glycemic Aged Glycated Hemoglobin business.industry Incidence (epidemiology) Type 2 Diabetes Mellitus General Medicine Middle Aged medicine.disease Insulin Long-Acting Endocrinology Diabetes Mellitus Type 2 Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Ethnicitydisease. 27(1) |
| ISSN: | 1049-510X |
| Popis: | Objective: To evaluate the effectiveness and safety of insulin detemir treatment as add-on therapy in a real-world setting of Lebanese insulin naïve persons, with type 2 diabetes poorly controlled on oral antidiabetic drugs (OADs).Methods: Our study was a prospective, observational study representing the Lebanese arm of the multinational prospective and observational study involving 2,155 persons across Near East countries, Lebanon, Pakistan, Israel and Jordan. Effectiveness endpoints were changes in HbA1c, fasting and post-prandial glucose (FPG, PPG) after 24 weeks of treatment with insulin detemir in eligible persons. Safety endpoints were number of hypoglycemic events, incidence of adverse drug reactions (ADRs), serious ADRs, adverse events, and body weight change between baseline and end of treatment.Results: 868 persons were included (mean age: 59.5 ± 10.4 years, men: 55.3%). Glycemic control improved with significant reduction in mean HbA1c from 9.7 ± 1.6% to 7.2 ± 1% (PConclusions: Initiating insulin detemir in a clinical health care setting among Lebanese with type 2 diabetes mellitus on OADs improves glycemic control with no increase in hypoglycemia, adverse events or weight compared with baseline.Ethn Dis.2017;27(1):45-54; doi:10.18865/ed.27.1.45. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|